vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1409Research ArticleВ ПОМОЩЬ ВРАЧУA DOCTOR’S AIDБЕЗОПАСНОСТЬ ПРИМЕНЕНИЯ ИНТЕРФЕРОНА БЕТА-1А ДЛЯ ПОДКОЖНОГО ВВЕДЕНИЯ У ДЕТЕЙ И ПОДРОСТКОВ С РАССЕЯННЫМ СКЛЕРОЗОМSAFETY OF INTERFERON BETA 1A FOR A SUBCUTANEOUS ADMINISTRATION IN CHILDREN AND ADOLESCENTS WITH DISSEMINATED SCLEROSISБыковаО.В.BykovaO.V.ПлатоноваА.Н.PlatonovaA.N.ГольцоваН.В.Gol'tsovaN.V.КузенковаЛ.М.KuzenkovaL.M.БойкоА.Н.BoikoA.N.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowRussian FederationРоссийский государственный медицинский университет, МоскваРоссияChair of Neurology and Neurosurgery, Russian State Medical University, MoscowRussian Federation20080511201573Вопросы современной педиатрии108112Copyright © Быкова О., Платонова А., Гольцова Н., Кузенкова Л., Бойко А., 20082008Быкова О., Платонова А., Гольцова Н., Кузенкова Л., Бойко А.Bykova O., Platonova A., Gol'tsova N., Kuzenkova L., Boiko A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1409ReferencesRosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Science. 2001; 22: 117–139.Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Science. 2001; 22: 117–139.Sadovnick A.D., Ebers G.C. Epidemiology of multiple sclerosis: a critical overview. Can J. Neurol. Sci. 1993; 20: 17–29.Sadovnick A.D., Ebers G.C. Epidemiology of multiple sclerosis: a critical overview. Can J. Neurol. Sci. 1993; 20: 17–29.Boiko F., Vorobeychik G., Paty D. et al. Early onset of multiple sclerosis: a longitudinal study. Neurology. 2002; 59 (7): 1006–1010.Boiko F., Vorobeychik G., Paty D. et al. Early onset of multiple sclerosis: a longitudinal study. Neurology. 2002; 59 (7): 1006–1010.Ghezzi A., Pozzilli C., Liguori M. et al. Prospective study of multiple sclerosis with early onset? Multiple sclerosis. 2002; 8 (2): 115–118.Ghezzi A., Pozzilli C., Liguori M. et al. Prospective study of multiple sclerosis with early onset? Multiple sclerosis. 2002; 8 (2): 115–118.Pinhas-Hamiel O., Sarova–Pinhas I., Achrion A. Multiple sclerosis in childhood and adolescence: Clinical features and management. Paediatr. Drugs. 2001; 3 (5): 329–336.Pinhas-Hamiel O., Sarova–Pinhas I., Achrion A. Multiple sclerosis in childhood and adolescence: Clinical features and management. Paediatr. Drugs. 2001; 3 (5): 329–336.Shaw C.M., Alvord E.C. Multiple sclerosis beginning in infancy. J. Child. Neurology. 1987; 2: 252–256.Shaw C.M., Alvord E.C. Multiple sclerosis beginning in infancy. J. Child. Neurology. 1987; 2: 252–256.Waubant E., Hietpas J., Stewart T. et al. Interferon beta–1ᾳ in children with multiple sclerosis is well tolerated. Neuropediatrics. 2001; 32 (4): 211–213.Waubant E., Hietpas J., Stewart T. et al. Interferon beta–1ᾳ in children with multiple sclerosis is well tolerated. Neuropediatrics. 2001; 32 (4): 211–213.Быкова О.В., Маслова О.И., Гусева М.Р. и др. Рассеянный склероз у детей и подростков: история изучения проблемы и современный опыт иммуномодулирующего лечения. Журнал неврологии и психиатрии. 2004; 4: 4–10.Быкова О.В., Маслова О.И., Гусева М.Р. и др. Рассеянный склероз у детей и подростков: история изучения проблемы и современный опыт иммуномодулирующего лечения. Журнал неврологии и психиатрии. 2004; 4: 4–10.Bosley E.B., Capildeo R. Early use of interferon in patients with multiple sclerosis. Clinical Practice. 2002; Suppl.131: 17–22.Bosley E.B., Capildeo R. Early use of interferon in patients with multiple sclerosis. Clinical Practice. 2002; Suppl.131: 17–22.Panitch H., Goodin D.S., Francis G. et al. Randomized, comparative study of interferon-b-1a treatment regimens in MS. The Evidence Trial. Neurology. 2002; 59: 1496–1506.Panitch H., Goodin D.S., Francis G. et al. Randomized, comparative study of interferon-b-1a treatment regimens in MS. The Evidence Trial. Neurology. 2002; 59: 1496–1506.Durelli L., Ferrero B., Ghezzi A. et al. The Independent Comparison of Interferon (INCOMIN) Trial: a multicenter randomized trial comparing clinical and MRI efficacy of IFN beta-1a and beta-1b in multiple sclerosis (abstract). Neurology. 2001; 56 (Suppl. 3): 148.Durelli L., Ferrero B., Ghezzi A. et al. The Independent Comparison of Interferon (INCOMIN) Trial: a multicenter randomized trial comparing clinical and MRI efficacy of IFN beta-1a and beta-1b in multiple sclerosis (abstract). Neurology. 2001; 56 (Suppl. 3): 148.Fischer J.S., Rudick R.A., Cutter G.R. et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult. Scler. 1999; 5: 244–250.Fischer J.S., Rudick R.A., Cutter G.R. et al. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult. Scler. 1999; 5: 244–250.Cборник стандартов оказания дорогостоящей (высокотехнологической) медицинской помощи Минздравсоцразвития России.Cборник стандартов оказания дорогостоящей (высокотехнологической) медицинской помощи Минздравсоцразвития России.
The authors declare that there are no conflicts of interest present.